Fifty-one patients with gonadal dysgenesis receiving estrogen progesterone replacement therapy for periods of six months to twenty years were studied. Endometrial biopsies or dilatation and curettage were obtained in forty-seven patients. One patient on diethylstilbesterol had atypical endometrial hyperplasia which progressed to adenoepidermoid carcinoma. Six patients had benign cystic hyperplasia. Endometrial abnormalities occurred in patients with a duration of estrogen therapy greater than 3-5/12 years and who received a total lifetime estrogen dose exceeding 2500 mg of conjugated estrogen or its equivalent. Five patients who developed endometrial hyperplasia had taken cyclic estrogen-progesterone therapy; the sixth took unopposed estrogen therapy.
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Fifty-one patients with gonadal dysgenesis receiving estrogen progesterone replacement therapy for periods of six months to twenty years were studied. Endometrial biopsies or dilatation and curettage were obtained in forty-seven patients. One patient on diethylstilbesterol had atypical endometrial hyperplasia which progressed to adenoepidermoid carcinoma. Six patients had benign cystic hyperplasia. Endometrial abnormalities occurred in patients with a duration of estrogen therapy greater than 3-5/12 years and who received a total lifetime estrogen dose exceeding 2500 mg of conjugated estrogen or its equivalent. Five patients who developed endometrial hyperplasia had taken cyclic estrogen-progesterone therapy; the sixth took unopposed estrogen therapy.
Total nuclear estradiol binding was measured in six patients with Turner Syndrome and nine control women. Two of the Turner patients had endometrial hyperplasia. Nuclear binding in these two subjects did not differ from that of the other patients witt Turner Syndrome. Nuclear binding in the Turner patients (range 3-lOl/DPM ng DNA) was not different from that of nine control women at comparable stages of the menstrual cycle (34-429 DPM/ng DNA). Growth hormone (GH) secretion was monitored continuously over 24 hours in 23 children with IDD to investigate the hypothesis that GH secretion evaluated in a physiologic fashion reflects the degree of ambiant glycemia. A constant blood withdrawal system was used on ambulatory subjects who otherwise were maintained on their usual diabetic routine.
All of the subjects studied had long standing insulin dependn c y and none exhibited clinical or biochemical evidence of hypo. 'lycemia during the study period. Eight normal children (NC) were similarlv studied. 
Group

** Linear regression analysis
Examination of the diurnal pattern of GH secretion revealed 10 difference in number of secretion episodes or in the ratio of swake/asleep GH secretion. Despite the normal mean ICGH, con-:iderable individual variation in GH levels in IDD was observed. In additional 13 patients with IDD, not included with these data 2ecause of hypoglycemia, also had a normal mean ICGH and comparnbly wide individual variation.
Conclusion: There is no direct relationship between GH secret .on and the degree of hyperglycemia in IDD.
in three patients receiving oxymetholone for aplastic anemia (AA), an association not preThe mean glucose of the seven patients receiving oxymetholone as elevated during OGTT (p<0.001 for each sampling time). TIRI as elevated in five of these patients (pC0. 05-0.001 d over 8 mos. to 26 ~g/ml. A GnRH test (2.%g/kg iv) was done uring initial evaluation of all girls. Basal serum LH values or group A (6.621.6,MASE) and B (4.1A0.6) were not significantl: ifferent; basal serum FSH values for A(10.0+_2.9) were signifi-'rls fell within or above the normal adult range and in one gir as normal for bone age. Three girls in B had no LH or FSH reponses and 2 had low prepubertal responses. All 3 girls who ailed to respond to GnRH had intermittent leukorrhea and breast nlargement and one had normal appearing ovaries on laparo:,copy. Collinge. YcGill Ihiversitv-Vontreal Children's Hosp, mandole, cefachlor, tetracycline and trimethoprim-sulfamethoxazole were evaluated using a microtiter broth dilution method. 70% of strains were resistaqt to Lamp1 of 110 ug/ml (MIC range = 4-128 ug/ml), while all were inhibited by ~1 ug/ml of chloramphenicol (MIC=0.25-1 ug/ml). Strains were highly susceptible to cefamandole (90% inhibited by 50.5 ug/ml), although only 25% of strains were inhibited by 51 11g/ml of cefachlor (MIC-1-16 pg/ml). All isolates were inhibited by [tetracycline1 of 51 ug/ml. MICs of TMP-SMZ ranged from .0037/.148-.125/2.37 u g h 1 with 75% of strains susceptible to 50.03/.59 ug/ml. The incidence of B-lactanase (+I Hemophilus strains in Michigan appears to be increasing. These strains are highly susceptible ln vitro to chloramphenicol, cefamandole and TMP-SMZ.
Rational and safe use of drugs includes weighing the indication of a drug versus the risk of reactions. 110 instances of drug use were analyzed in 27 neonates with 47 identified drug reactions. Birth weight, gestational age, admission age and length of hospital stay ranged from 835-3570 g, 24-41 wks, 0.5 -65 days, and 0.5 -100 days respectively. To assess the accurac) of drug use the depree of indication at initiation of therapy was compared to that at discharge or completion of therapy. 9 degrees (definite, presumptive but highly indicated, resuscitative, prophylactic, procedure-related, empirical, palliative, not indicated, not classified) were based on set clinical, laboratory and pharmacologic criteria. 113 of drug use was definitely indicated. Of 21 drugs initially presumed highly indicated, 7 became definitely indicated, but 7 were not indicated, suggesting overtreatment in at least 30% of presumed-indicated drugs. Adverse drug reactions were noted in many drugs not definitely indicated, suggestinp that risk may he greater than benefit. Data underscore the need for more careful and rational use of drui Indication0
Initial C(%) Final 
